MDT
NYSEHealthcareLoading…
Medtronic plc. Ordinary Shares
Sector: Healthcare•United States•Market Cap: $112.8B
Related News
Latest stories connected to MDT
10/19More news →
- RS 75Medtronic gets US FDA nod to use surgical system in cranial, ENT surgeriesReuters•12h ago•Original source
- RS 75MDT Expands Agreement With Merit to Offer ViaVerte: Stock to Gain?Zacks Investment Research•2d ago•Original source
- RS 75Medtronic (MDT) Down 11.5% Since Last Earnings Report: Can It Rebound?Zacks Investment Research•Mar 19, 2026•Original source
- RS 75Medtronic: Snatch Up This Dividend Aristocrat Bargain NowSeeking Alpha•Mar 17, 2026•Original source
- RS 75I'm Buying Dividend Aristocrats At Bargain Basement PricesSeeking Alpha•Mar 16, 2026•Original source
- RS 75Medtronic, Inc. (NYSE:MDT) Targets Growth with Strategic AcquisitionFinancial Modeling Prep•Mar 10, 2026•Original source
- RS 75Medtronic plc (MDT) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking Alpha•Mar 10, 2026•Original source
Financials
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|
| Revenue | — | 32.36B | — | 31.69B | 30.12B | — | 30.56B | 29.95B | 29.71B | 28.83B |
| Cost of Revenue | — | 11.22B | — | 10.14B | 10.48B | — | 9.15B | 9.07B | 9.29B | 9.14B |
| Gross Profit | — | 21.15B | — | 21.54B | 19.63B | — | 21.40B | 20.89B | 20.42B | 19.69B |
| Research and Development Expenses | — | 2.73B | — | 2.75B | 2.49B | — | 2.33B | 2.26B | 2.19B | 2.22B |
| General and Administrative Expenses | — | 0 | — | 0 | 0 | — | 0 | 0 | 0 | 0 |
| Selling and Marketing Expenses | — | 0 | — | 0 | 0 | — | 0 | 0 | 0 | 0 |
| Selling General and Administrative Expenses | — | 10.74B | — | 10.29B | 10.15B | — | 10.42B | 10.24B | 10.02B | 9.47B |
| Other Expenses | — | 2.53B | — | 2.75B | 2.51B | — | 2.39B | 1.75B | 2.82B | 2.64B |
| Operating Expenses | — | 16.00B | — | 15.79B | 15.15B | — | 15.13B | 14.25B | 15.03B | 14.33B |
| Cost and Expenses | — | 27.22B | — | 25.93B | 25.63B | — | 24.29B | 23.31B | 24.33B | 23.47B |
| Net Interest Income | — | -719.00M | — | -553.00M | -925.00M | — | -1.44B | -1.15B | -1.09B | -955.00M |
| Interest Income | — | 0 | — | 0 | 0 | — | 0 | 0 | 0 | 431.00M |
| Interest Expense | — | 719.00M | — | 553.00M | 925.00M | — | 1.44B | 1.15B | 1.09B | 1.39B |
| Depreciation and Amortization | — | 2.65B | — | 2.71B | 2.70B | — | 2.66B | 2.64B | 2.92B | 2.82B |
| EBITDA | — | 8.20B | — | 8.78B | 7.52B | — | 9.30B | 9.46B | 8.61B | 8.54B |
| EBIT | — | 5.56B | — | 6.07B | 4.82B | — | 6.64B | 6.82B | 5.70B | 5.72B |
| Non Operating Income Excluding Interest | — | -412.00M | — | -318.00M | -336.00M | — | -373.00M | -181.00M | -313.00M | -361.00M |
| Operating Income | — | 5.14B | — | 5.75B | 4.48B | — | 6.27B | 6.64B | 5.38B | 5.36B |
| Total Other Income Expenses Net | — | -307.00M | — | -235.00M | -589.00M | — | -1.07B | -965.00M | -781.00M | -1.02B |
| Income Before Tax | — | 4.84B | — | 5.52B | 3.90B | — | 5.20B | 5.67B | 4.60B | 4.34B |
| Income Tax Expense | — | 1.13B | — | 456.00M | 265.00M | — | 547.00M | 2.58B | 578.00M | 798.00M |
| Net Income From Continuing Operations | — | 3.70B | — | 5.06B | 3.63B | — | 4.65B | 3.10B | 4.02B | 3.54B |
| Net Income From Discontinued Operations | — | 0 | — | 0 | 0 | — | 0 | 0 | 0 | 0 |
| Other Adjustments To Net Income | — | -1.00M | — | -1.00M | 0 | — | 0 | 0 | 0 | 0 |
| Net Income | — | 3.68B | — | 5.06B | 3.63B | — | 4.65B | 3.10B | 4.02B | 3.54B |
| Net Income Deductions | — | 0 | — | 0 | 0 | — | 0 | 0 | 0 | 0 |
| Borrom Line Net Income | — | — | — | — | — | — | — | — | — | — |
| EPS | — | 2.77 | — | 3.75 | 2.68 | — | 3.44 | 2.29 | 2.92 | 2.51 |
| EPS Diluted | — | 2.76 | — | 3.73 | 2.66 | — | 3.41 | 2.27 | 2.89 | 2.48 |
| Weighted Average SHS Out | — | 1.33B | — | 1.34B | 1.34B | — | 1.35B | 1.36B | 1.38B | 1.41B |
| Weighted Average SHS Out Dil | — | 1.33B | — | 1.35B | 1.35B | — | 1.36B | 1.37B | 1.39B | 1.43B |
| Fiscal Year (FMP) | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K |
| Gross Profit Margin | 0.65 | 0.65 | 0.66 | 0.68 | 0.65 | 0.67 | 0.7 | 0.7 | 0.69 | 0.68 |
| R&D to Revenue | 0.08 | 0.08 | 0.09 | 0.09 | 0.08 | 0.08 | 0.08 | 0.08 | 0.07 | 0.08 |
| SG&A to Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Burden | 0.89 | 0.87 | 0.89 | 0.91 | 0.81 | 0.79 | 0.78 | 0.83 | 0.81 | 0.76 |
| EBIT Margin | 0.19 | 0.17 | 0.19 | 0.19 | 0.16 | 0.18 | 0.22 | 0.23 | 0.19 | 0.2 |
| EBITDA Margin | 0.27 | 0.25 | 0.28 | 0.28 | 0.25 | 0.27 | 0.3 | 0.32 | 0.29 | 0.3 |
| EBT per EBIT | 0.95 | 0.94 | 0.98 | 0.96 | 0.87 | 0.85 | 0.83 | 0.85 | 0.85 | 0.81 |
| Effective Tax Rate | 0.17 | 0.23 | 0.29 | 0.08 | 0.07 | -0.19 | 0.11 | 0.45 | 0.13 | 0.18 |
| Tax Burden | 0.83 | 0.76 | 0.7 | 0.91 | 0.93 | 1.18 | 0.89 | 0.55 | 0.88 | 0.82 |
| Cont. Operations Profit Margin | 0.14 | 0.11 | 0.12 | 0.16 | 0.12 | 0.17 | 0.15 | 0.1 | 0.14 | 0.12 |
| Bottom Line Profit Margin | 0.14 | 0.11 | 0.12 | 0.16 | 0.12 | 0.17 | 0.15 | 0.1 | 0.14 | 0.12 |
| Operating Cycle | 242.74 | 238.89 | 250.34 | 230.02 | 216.37 | 222.43 | 223.95 | 217.03 | 199.78 | 209.07 |
| Fwd PEG Ratio | 0.75 | -13.58 | -1.31 | 0.7 | -1.96 | 7.36 | 0.51 | -1.62 | 1.75 | 10.99 |
| Earnings Yield | 0.04 | 0.03 | 0.03 | 0.04 | 0.02 | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 |
| Income Quality | 1.5 | 1.85 | 1.6 | 1.45 | 1.72 | 1.51 | 1.51 | 1.51 | 1.71 | 1.47 |